SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Kelun-Biotech Presents Final Overall Survival Results From OptiTROP-Lung04

Kelun-Biotech said the prespecified final overall survival analysis from its Phase III OptiTROP-Lung04 study was presented at the 2026 ESMO Congress.

Related stories